Vitamin D and Calcium to Prevent Hip Fractures in Elderly Women

Chapuy, M. C.; Arlot, M; Duboeuf, F.; Brun, Johan G.; Crouzet, Brigitte; Arnaud, S; Delmas, PD; Meunier, Pierre J.

doi:10.1097/00019616-199303000-00021

Cited by 215 publications

(323 citation statements)

References 0 publications

Supporting

Mentioning

291

Contrasting

Unclassified

Order By: Relevance

“…However, other authors have proposed lower and higher levels as cutoff values: 12-16 ng/ ml (Ooms et al, 1995;Gloth et al, 1995;Thomas et al, 1998) and 44 ng/ml, respectively . This last value is very similar to the level proposed as being desirable to diminish fracture risk (Chapuy et al, 1992;Mc Kenna & Freaney, 1998).…”

Section: Discussionsupporting

confidence: 78%

“…Other studies have shown that bone resorption markers are also higher in women, and most likely this increased bone turnover status is in part responsible for the increased rate of bone fragility fractures found almost universally in women. This finding emphasizes the importance of correcting vitamin D deficiency/insufficiency in women, as it has proved to be efficacious in reducing the rate of bone fracture (Chapuy et al, 1992(Chapuy et al, , 2002.…”

Section: Discussionmentioning

confidence: 71%

“…The threshold of serum 25OHD that separates vitamin D sufficiency from insufficiency is generally defined by its biological effect, primarily by the increase in serum parathormone. A new category of desirable levels has been introduced, based on the 25OHD levels required to diminish hip fractures (Chapuy et al, 1992;Mc Kenna & Freaney, 1998). Reports in the literature have established serum 25OHD levels below which PTH begins to increase to be between 12 and 20 ng/ml (Bouillon et al, 1987;Gloth et al, 1995;Ooms et al, 1995;Mc Kenna & Freaney, 1998).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

High prevalence of vitamin D insufficiency in healthy elderly people living at home in Argentina

et al. 2004

View full text Add to dashboard Cite

Objective: To evaluate the nutritional status of vitamin D in urban populations of healthy elderly people living at home, in different regions of Argentina. Design: Cross-sectional study. Subjects: In total, 386 ambulatory subjects over 65 y of age from seven cities (between latitude 261S and 551S) were asked to participate between the end of winter and the beginning of spring. Of these, 369 accepted, 30 were excluded because of medical history or abnormal biochemical determinations. Finally, 339 subjects (226 women and 113 men) (X7s.d.) (71.37 5.2 y) were included. Results: Serum 25OHD levels were lowest in the South (latitude range: 411S-551S): 14.275.6 ng/ml (Po0.0001vs North and Mid regions); highest in the North (261S-271S): 20.777.4 ng/ml (Po0.03 vs Mid, Po0.0001vs South); and intermediate in the Mid region (331S-341S) 17.978.2 ng/ml. Serum mid-molecule PTH (mmPTH) and 25OHD were inversely related: (r ¼ À0.24, Po0.001). A cutoff level of 25OHD at which serum mmPTH levels began to increase was established at 27 ng/ml. A high prevalence (87-52%) of subjects with 25OHD levels in the deficiency-insufficiency range (25OHD levels o20 ng/ml) was detected. Conclusion: This study shows that vitamin D deficiency/insufficiency in the elderly is a worldwide problem. Correction of this deficit would have a positive impact on bone health of elderly people. Sponsorship: Asociació n Argentina de Osteología y Metabolismo Mineral (AAOMM).

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 71%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High prevalence of vitamin D insufficiency in healthy elderly people living at home in Argentina

et al. 2004

View full text Add to dashboard Cite

show abstract

“…(14)(15)(16)(17)32) Histomorphometry showed that vitamin D analogues can stimulate bone-formation activity on cortical and trabecular bone surfaces; however, bone-formation activity was best demonstrated at hypercalcemic doses. (14,15) Similarly in clinical studies, skeletal efficacy was demonstrated for vitamin D analogues, including reduction of nonvertebral fractures, (5)(6)(7) but the realization of bone efficacy in the absence of hypercalcemia or hypercalciuria has been difficult to achieve. (6)(7)(8)(9)(10)33) We hypothesized that nonsecosteroidal vitamin D receptor ligands could be synthesized to preferentially modulate skeletal efficacy over hypercalcemic effects in vivo.…”

Section: Discussionmentioning

confidence: 99%

“…(5)(6)(7)(8) However, vitamin D analogues were shown to dose-dependently elevate calcium in sera and in urine, leading to concerns about hypercalcemia and hypercalciuria in humans (5,6,(9)(10)(11)(12)(13) and in animals. (14)(15)(16)(17)(18) ORIGINAL ARTICLE…”

Section: Introductionmentioning

confidence: 99%

A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia

Sato

Iturria

et al. 2010

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Vitamin D 3 analogues were shown to be beneficial for osteoporosis and other indications, but their narrow therapeutic window between efficacy and hypercalcemia has limited their clinical utility. A nonsecosteroidal, tissue-selective, orally bioavailable, vitamin D receptor (VDR) ligand was ascertained to be efficacious in bone while having modest calcemic effects in vivo. This compound (VDRM2) potently induced Retinoid X Receptor alpha (RXR)-VDR heterodimerization (EC 50 ¼ 7.1 AE 1.6 nM) and induced osteocalcin promoter activity (EC 50 ¼ 1.9 AE 1.6 nM). VDRM2 was less potent in inducing Ca 2þ channel transient receptor potential cation channel, subfamily V, member 6 (TRPV6) expression (EC 50 ¼ 37 AE 12 nM). VDRM2 then was evaluated in osteopenic ovariectomized (OVX) rats and shown to dose-dependently restore vertebral bone mineral density (BMD) from OVX to sham levels at 0.08 mg/kg per day. Hypercalcemia was observed at a dose of 4.6 mg/kg per day of VDRM2, suggesting a safety margin of 57 [90% confidence interval (CI) 35-91]. 1a,25-dihydroxyvitamin D 3 [1a,25(OH) 2 D], ED71, and alfacalcidol restored BMD at 0.030, 0.0055, and 0.046 mg/kg per day, respectively, whereas hypercalcemia was observed at 0.22, 0.027, and 0.23 mg/kg per day, indicating a safety margin of 7.3, 4.9, and 5.0, respectively (90% CIs 4.1-13, 3.2-7.7, and 3.5-6.7, respectively). Histomorphometry showed that VDRM2 increased cortical bone area and stimulated the periosteal bone-formation rate relative to OVX at doses below the hypercalcemic dose. By contrast, ED71 increased the periosteal boneformation rate only above the hypercalcemic dose. VDRM2 suppressed eroded surface on trabecular bone surfaces at normal serum calcium dosage levels, suggesting dual anabolic and antiresorptive activity. In summary, vitamin D analogues were more potent than VDRM2, but VDRM2 had a greater safety margin, suggesting possible therapeutic potential. ß

show abstract

Sustained-Release Sodium Fluoride in the Treatment of the Elderly With Established Osteoporosis

Rubin¹,

Pak²,

Adams‐Huet³

et al. 2001

Arch Intern Med

View full text Add to dashboard Cite

show abstract

Vitamin D and Calcium to Prevent Hip Fractures in Elderly Women

Cited by 215 publications

References 0 publications

High prevalence of vitamin D insufficiency in healthy elderly people living at home in Argentina

High prevalence of vitamin D insufficiency in healthy elderly people living at home in Argentina

A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia

Sustained-Release Sodium Fluoride in the Treatment of the Elderly With Established Osteoporosis

Contact Info

Product

Resources

About